Coimmuna

Coimmuna is a pre-clinical stage biotechnology company focused on the development of novel cancer immunotherapies. The company specializes in targeting tumor-associated antigens, specifically Chondroitin Sulfate Proteoglycan 4 (CSPG4) and B7-H3, which are overexpressed in various aggressive solid tumors and the tumor microenvironment. Coimmuna's therapeutic approach includes the development of monoclonal antibodies, antibody-drug conjugates, and CAR-T cell therapies designed to overcome immune evasion. Founded by leading experts in tumor immunology from Massachusetts General Hospital, the company aims to address high unmet needs in indications such as melanoma, triple-negative breast cancer, and glioblastoma. Their research leverages deep expertise in the structural and functional properties of cell surface antigens to create highly specific targeted agents.